Asian Journal of Pharmaceutical Sciences最新文献

{"title":"Controlled release of berberine modulates the wound microbiome to accelerate wound healing","authors":"Zeyu Xu ,&nbsp;Lixiang Zhang ,&nbsp;Juntong Guo ,&nbsp;Qing Xia ,&nbsp;Zhengping Ge ,&nbsp;Ziyu Wang ,&nbsp;Ruoyu Mu ,&nbsp;Jie Dong ,&nbsp;Zhiguo Qin ,&nbsp;Jun Chen ,&nbsp;Yiwei Wang","doi":"10.1016/j.ajps.2026.101148","DOIUrl":"10.1016/j.ajps.2026.101148","url":null,"abstract":"<div><div>The wound microbiome has been shown to play a significant role in influencing the wound healing process. <em>Coptis chinensis</em>, a traditional Chinese medicine (TCM) known for its heat-clearing properties, contains berberine (BER) as major active ingredient, which exhibits notable antibacterial activity. In this study, we investigated the effect of BER on wound healing and wound microbiome through three distinct delivery strategies, including solution form, burst-release scaffolds (PCL/BER), and sustained-release scaffolds (PCL/PLGA/BER), compared with an untreated negative control (NC) group. Drug release studies confirmed that PCL/BER caused a pronounced burst release, while the incorporation of PLGA enabled sustained release of BER for up to 120 h. Further <em>in vivo</em> studies showed that the sustained BER release from the PCL/PLGA/BER resulted in the most effective improvement in wound healing. Microbiome analysis using 16S rRNA sequencing identified <em>Staphylococcus xylosus</em> (<em>S. xylosus</em>) as the key species influencing wound healing outcomes in response to BER delivery. <em>S. xylosus</em> overabundance in the NC group and its depletion in the BER solution and burst BER release groups impaired wound healing. In contrast, sustained BER delivery maintained an optimal <em>S. xylosus</em> abundance that promoted a favorable immune microenvironment by modulating CXCL10 and (IFN-α) expression. Our findings emphasize the importance of coordinating drug release kinetics with microbiome dynamics for optimal wound healing outcomes and provide valuable insights for developing future delivery systems for heat-clearing TCMs, with a focus on microbiome-modulation therapeutic strategies.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"21 2","pages":"Article 101148"},"PeriodicalIF":11.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147741204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microneedle Vaccine Printer Enables Decentralized and Thermostable mRNA Vaccine Delivery","authors":"","doi":"10.1016/j.ajps.2026.101115","DOIUrl":"10.1016/j.ajps.2026.101115","url":null,"abstract":"","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"21 2","pages":"Article 101115"},"PeriodicalIF":11.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147741272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ACQ-FRET dual-functional near-infrared fluorescent probes for the bioimaging of nanocarriers","authors":"Chang Liu ,&nbsp;Runtong Zhang ,&nbsp;Yi Lu ,&nbsp;Zongguang Tai ,&nbsp;Quangang Zhu ,&nbsp;Zhongjian Chen ,&nbsp;Wei Wu","doi":"10.1016/j.ajps.2026.101140","DOIUrl":"10.1016/j.ajps.2026.101140","url":null,"abstract":"<div><div>Förster resonance energy transfer (FRET) and aggregation-caused quenching (ACQ) are well-established mechanisms with promising potential to eliminate interference from free probes in studies of <em>in vivo</em> nanocarrier behavior. However, both approaches have a critical limitation, fluorescence reillumination. This problem arises when aggregates of quenched ACQ probe redisperse, or separated FRET probe pairs recouple, after repartitioning and enrichment in hydrophobic domains, leading to significant interference. To minimize reillumination, our study employs an “And” logic-gate strategy, integrating ACQ and FRET principles. We screened a series of near-infrared (NIR) fluorophores based on the BODIPY parent structures to identify an optimized ACQ-FRET dual-functional probe pair, where BDP1 was chosen as the donor and P1 as the acceptor. Compared to the individual donor (BDP1) or acceptor (P1), the ACQ-FRET probe pair dramatically reduced reillumination-derived interference in both plasma and cell line assays. Subsequent <em>in vivo</em> and <em>ex vivo</em> bioimaging confirmed the superior performance of the ACQ-FRET probe, which consistently exhibited the lowest reillumination interference (below 15%) among all tested probes. This performance significantly outperformed that of BDP1 (32%) and P1 (47%), and even exceeded P2 (19%), a well-established NIR probe characterized by relatively low reillumination.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"21 2","pages":"Article 101140"},"PeriodicalIF":11.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147741202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nose-to-brain delivery of donepezil within a small dose improves bioavailability and efficacy for Alzheimer’s disease treatment","authors":"Gang Wang ,&nbsp;Xuezhe Duan ,&nbsp;Defang Ouyang ,&nbsp;Jianping Zhou ,&nbsp;Huaqing Zhang ,&nbsp;Yang Ding","doi":"10.1016/j.ajps.2026.101130","DOIUrl":"10.1016/j.ajps.2026.101130","url":null,"abstract":"<div><div>Oral administration of donepezil (Don) is the first-line medication for Alzheimer’s disease (AD); however, the dysphagia of elderly patients and severe gastrointestinal side effects substantially restrict administration compliance. Herein, we exploit a nose-to-brain pathway for Don administration to obtain smaller dosage but higher intracerebral bioavailability (BA), thereby achieving inhibition of acetylcholinesterase (AChE) activity and avoiding side effects. With respect to the intranasal administration design, a patient-friendly Don nasal spray without preservatives was developed. The administration of Don nasal spray demonstrated good nasal deposition and mucosa permeation ability comparable to that of the model drug propranolol. The mice intranasally administered Don at an equivalent oral dose (0.65 mg/kg) demonstrated rapid brain distribution (∼5 min) and long-lasting AChE inhibition effects (72 h). To obtain the optimal intranasal dose, a dose-descending study was conducted by cascading the oral dosage at a 1:3 ratio. The results demonstrated that intranasal administration of Don at 0.07 mg/kg resulted in intracerebral BA and AChE inhibition comparable to oral administration at 0.65 mg/kg, suggesting an 89% dose reduction. Compared with oral administration, anti-AD effectiveness was evaluated in AD model mice after 34-d- intranasal administration of Don, resulting in a shorter onset time, higher intracerebral drug concentration, and a longer duration of AChE inhibition (0.07 mg/kg). The nasal and systemic safety of intranasal administration of Don was confirmed in an allergic rhinitis mouse model after 4 weeks of intranasal administration. Thus, a small dose of Don exhibits improved intracerebral BA and AChE inhibition via intranasal administration, thereby offering better compliance and reducing side effects in AD treatment.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"21 2","pages":"Article 101130"},"PeriodicalIF":11.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147587939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MMP-9-responsive contact lens facilitating disease-adaptive and safer dexamethasone delivery for corneal neovascularization therapy","authors":"Chenxiao Chu ,&nbsp;Xi Chen ,&nbsp;Yaxin Deng ,&nbsp;Jie Zhang ,&nbsp;Xiaoshuang Bi ,&nbsp;Yunfeng Ma ,&nbsp;Mingli Wei ,&nbsp;Jiansong Zhao ,&nbsp;Haibing He ,&nbsp;Jingxin Gou ,&nbsp;Tian Yin ,&nbsp;Xing Tang ,&nbsp;Li Yang ,&nbsp;Yu Zhang","doi":"10.1016/j.ajps.2026.101146","DOIUrl":"10.1016/j.ajps.2026.101146","url":null,"abstract":"<div><div>Corneal neovascularization (CNV), an inflammation-driven pathological process responsible for irreversible vision loss, remains an urgent unmet challenge in ophthalmic medicine. Current interventions—ranging from surgery to topical steroids—fail to prevent recurrence or avoid severe side effects like intraocular hypertension and even corneal ulceration. Here, we introduce CL-Peptide-Dex, a transformative contact lens (CL) engineered for matrix metalloproteinase-9 (MMP-9)-responsive dexamethasone (Dex) release, to resolve this decades-long challenge. By grafting dexamethasone onto the lens surface via an MMP-9-cleavable peptide linker (GPLGLAGC), CL-Peptide-Dex achieves disease-adaptive drug delivery: rapid release during acute inflammation and sustained release throughout CNV progression. Unlike conventional drug-eluting systems, this surface-grafting strategy eliminates burst release while preserving lens transparency and oxygen permeability. In the rabbit corneal neovascularization model, a single administration of CL-Peptide-Dex could maintained a stable Dex level for 7 d, suppressed VEGF by 77.5%, and reduced neovascular area by 79.5%. Critically, CL-Peptide-Dex avoided intraocular pressure spikes and exhibited good corneal biocompatibility and compliance, enabling safe extended wear. By integrating MMP-9-responsive precision delivery with a patient-friendly design, CL-Peptide-Dex represents a significant advance in precision ophthalmology.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"21 2","pages":"Article 101146"},"PeriodicalIF":11.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147741268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted delivery of glucocerebrosidase to lysosomes: The LYSOTAC (LYSOsome-TArgeting Chimera) technology","authors":"Hee-Yeon Kim ,&nbsp;Eun Nam Choi ,&nbsp;Gee Eun Lee ,&nbsp;Sanghwa Yoon ,&nbsp;Su Ran Mun ,&nbsp;Eui Jung Jung ,&nbsp;Minji Kim ,&nbsp;Hyomin Lim ,&nbsp;Yang Jae Kang ,&nbsp;Woo-Jae Park ,&nbsp;Yong Tae Kwon ,&nbsp;Joo-Won Park","doi":"10.1016/j.ajps.2026.101149","DOIUrl":"10.1016/j.ajps.2026.101149","url":null,"abstract":"<div><div>Lysosomal storage diseases (LSDs) are a group of inherited metabolic disorders caused by misfolding of lysosomal proteins and their degradation via endoplasmic reticulum-associated degradation (ERAD). Deficiency in LSD-associated enzymes leads to the accumulation of toxic materials within the lysosome. In macroautophagy (hereafter autophagy), autophagic receptors as represented by p62/SQSTM1/Sequestosome-1 collect and deliver their cargoes to the lysosome. Here, we developed the LYSOTAC (LYSOsome-TArgeting Chimera) technology, which enables lysosomal targeting of LSD-associated enzymes while preserving their enzymatic activities. LYSOTAC employs a bifunctional chimera that simultaneously binds an LSD-associated enzyme via the enzyme-binding ligand (EBL) and p62 via the autophagy-targeting ligand (ATL). Upon binding, p62 undergoes self-polymerization to form cargo-p62 complexes, which are sequestered into autophagosomes and delivered to lysosomes, where the enzymes exhibit maximal activity. Here, LYSOTAC compounds targeting β-glucocerebrosidase (GCase) were designed to restore GCase activity in lysosomes and promote glucosylceramide degradation in Gaucher disease fibroblasts. We suggest that LYSOTAC provides a potential therapeutic strategy for LSDs.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"21 2","pages":"Article 101149"},"PeriodicalIF":11.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147741269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular origin, discovery, validation and application of neoantigens","authors":"Qian Lyu ,&nbsp;Shen Hu","doi":"10.1016/j.ajps.2026.101143","DOIUrl":"10.1016/j.ajps.2026.101143","url":null,"abstract":"<div><div>Neoantigens, tumor-specific peptides originating from somatic mutations, are pivotal targets for personalized cancer immunotherapy. This review synthesizes current neoantigen research, encompassing its molecular origins, discovery methodologies, validation strategies and translational applications. We emphasize integrated genomics, mass spectrometry-based immunopeptidomics and machine learning-enhanced bioinformatics pipelines that are concurrently used to predict neoantigen processing, major histocompatibility complex (MHC)-binding affinity, and immunogenicity. Neoantigen-targeted vaccines demonstrate promising efficacy in solid tumors while combinatorial approaches integrating neoantigen-directed therapies with other immunotherapeutics show significant potential to overcome tumor immune evasion mechanisms and improve treatment outcomes. These new progresses underscore the critical role of neoantigens in advancing precision cancer immunotherapy.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"21 2","pages":"Article 101143"},"PeriodicalIF":11.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147741201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in nanotechnology for the diagnosis and management of autoimmune diseases","authors":"Yongquan Zheng ,&nbsp;Xiaoyu Cai ,&nbsp;Lyu Zhang ,&nbsp;Weidong Fei ,&nbsp;Dongxu Qin ,&nbsp;Xiaoqian Zhang ,&nbsp;Jimin Zhu ,&nbsp;Caihong Zheng ,&nbsp;Yao Yao","doi":"10.1016/j.ajps.2026.101144","DOIUrl":"10.1016/j.ajps.2026.101144","url":null,"abstract":"<div><div>Autoimmune diseases (AIDs) are chronic, heterogeneous disorders that are often diagnosed after irreversible tissue damage and treated with broad immunosuppression that fails to deliver durable remission. Nanotechnology offers opportunities to sense early immune perturbations and to deliver interventions with molecular, cellular and organ-level precision. Here we synthesize advances from 2015 to 2025 in nano-enabled diagnosis and therapy for rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease, type 1 diabetes, psoriasis and selected rare AIDs. On the diagnostic side, nano-optical and electrochemical biosensors, nano-enhanced imaging probes, and liquid-biopsy platforms for extracellular vesicles and cell-free nucleic acids improve sensitivity, stratification and longitudinal monitoring, while wearable and point-of-care devices extend assessment into home and community settings. We relate these technologies to concrete clinical scenarios and highlight performance metrics such as limit of detection, sample volume, and clinical sensitivity/specificity. Therapeutically, we review stimuli-responsive and ligand-targeted nanocarriers for small molecules and biologics, tolerogenic nanoparticles and exosomes, mRNA–lipid nanoparticle \"inverse vaccines\", and microneedles or tissue-nanotransporter systems for local gene and cytokine modulation. We summarize emerging clinical trial data and currently marketed nanomedicines for autoimmune indications, linking formulation design to efficacy and safety readouts. Across platforms, we outline design principles connecting physicochemical properties to biodistribution and immune interactions, and we discuss manufacturability, long-term safety and regulatory hurdles that govern translation. Collectively, these advances, together with emerging AI and digital twin frameworks, illustrate how nanotechnology can support earlier diagnosis, more precise and tolerogenic interventions, and progress toward durable, personalized remission in AIDs.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"21 2","pages":"Article 101144"},"PeriodicalIF":11.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147741270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An exosome-inspired docetaxel prodrug nanoplatform for potent STING activation and synergistic chemoimmunotherapy","authors":"Xinying Wang ,&nbsp;Xianlu Zhang ,&nbsp;Zixuan Jiao ,&nbsp;Shipeng Ning ,&nbsp;Hanping Wang ,&nbsp;Hui Liu ,&nbsp;Lifen He ,&nbsp;Haonan Li ,&nbsp;Mingzhong Li ,&nbsp;Kaiyuan Wang ,&nbsp;You Pan ,&nbsp;Zhonggui He","doi":"10.1016/j.ajps.2026.101139","DOIUrl":"10.1016/j.ajps.2026.101139","url":null,"abstract":"<div><div>The treatment of triple-negative breast cancer (TNBC) is significantly hampered by its immunosuppressive tumor microenvironment and limited T-cell infiltration. Activating the STING pathway presents a promising therapeutic avenue due to its potential to trigger a robust innate immune response and remodel the immunosuppressive landscape, thereby sensitizing tumors to immunotherapy. To harness this potential, we developed an exosome-mimetic nanoplatform (EMMDs). EMMDs is fabricated by co-loading a disulfide-linked docetaxel prodrug (DTX-SS-PA) and the STING agonist MSA-2 into polymeric micelles and further decorated with homotypic tumor cell-derived exosomal membrane (EM). This biomimetic design confers superior tumor-targeting capability. Upon reaching the tumor site, the prodrug is specifically activated to release cytotoxic docetaxel (DTX), while MSA-2 is concurrently released to potently activate the STING pathway. This dual action initiates a powerful antitumor immune response and reverses immunosuppression, leading to a synergistic chemo-immunotherapeutic outcome. In the murine TNBC model, EMMDs demonstrated remarkable antitumor efficacy, obviously provoking a robust STING-mediated type I interferon response and inhibiting tumor growth. This work presents a promising biomimetic strategy for remodeling the tumor immune microenvironment via efficient STING activation.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"21 2","pages":"Article 101139"},"PeriodicalIF":11.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147587956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual-functional self-assembled nanosystems with enhanced protease resistance: Promoting bacterial aggregation and immune activation for multidrug-resistant bacterial infection","authors":"Nan Gao,&nbsp;Yikuan Bian,&nbsp;Shasha Wang,&nbsp;Pengfei Bai,&nbsp;Chunyang Fang,&nbsp;Jiaqi Sun,&nbsp;Yihan Li,&nbsp;Na Dong,&nbsp;Anshan Shan,&nbsp;Jiajun Wang","doi":"10.1016/j.ajps.2026.101145","DOIUrl":"10.1016/j.ajps.2026.101145","url":null,"abstract":"<div><div>Multidrug-resistant bacterial infections are increasing globally and posing a greater threat to human health. The application of direct bactericidal agents can induce secondary infections and treatment failures. The antibacterial strategy of the innate immune system brings inspiration. Here, we developed highly stable bacterial-aggregating peptides with immunoregulatory function. These peptides were designed to capture multidrug-resistant bacteria, prevent their dissemination, and activate the antibacterial immune response of the host. Among these peptides, the central-bola amphiphile R₂F₄R₂ highly captured bacteria without directly killing them. R₂F₄R₂ was believed to self-assemble through the lateral connection of peptide chains. The tetra-Phe segments formed a hydrophobic core of nanoparticle, with Arg residues appearing on the surface. Notably, R₂F₄R₂ enhanced chemotactic response and phagocytic ability of macrophages, supported a transition to M2-macrophage phenotype to combat bacterial infection. Transcriptome sequencing and molecular docking analyses revealed that R₂F₄R₂ regulated the gene expression associated with immunoregulatory functions and modulated calcium-Rap1 signaling pathways. Finally, R₂F₄R₂ exhibited exceptional stability against proteolytic degradation and effectively entrapped invading pathogenic bacteria <em>Escherichia coli</em> to alleviate skin infections and intestinal inflammation. Overall, the bacterial-aggregating peptides represent a novel and effective strategy to combat multidrug-resistant infections.</div></div>","PeriodicalId":8539,"journal":{"name":"Asian Journal of Pharmaceutical Sciences","volume":"21 2","pages":"Article 101145"},"PeriodicalIF":11.9,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147741200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}